Nuvectis Pharma (NVCT) vs Olema Pharmaceuticals (OLMA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Nuvectis Pharma (NVCT) has outperformed Olema Pharmaceuticals (OLMA) over the past year, gaining 232.1% versus a loss of 23.9%. Olema Pharmaceuticals is the larger company by market cap ($694.7 million vs $662.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NVCT | OLMA |
|---|---|---|
| Share price | $20.29 | $7.94 |
| Market cap | $662.35M | $694.73M |
| 1-day change | +1.30% | +0.25% |
| YTD return | +168.74% | -68.24% |
| 1-year return | +232.08% | -23.95% |
| 5-year return | — | -74.15% |
| EPS (TTM) | $-1.31 | $-2.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $29.28 | $36.26 |
| 52-week low | $5.55 | $6.65 |
| Distance from 52-week high | -30.69% | -78.10% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +74.47% | +359.70% |
| Average volume | 219.45K | 1.07M |
| Shares outstanding | 32.64M | 87.50M |
| Employees | 16 | 150 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NVCT has outperformed OLMA by 256.0 percentage points over the past year.
About Nuvectis Pharma
NVCT stock →Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors.
Healthcare · Biotechnology · 16 employees
About Olema Pharmaceuticals
OLMA stock →Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer.
Healthcare · Biotechnology · 150 employees
NVCT vs OLMA FAQ
Which is bigger, Nuvectis Pharma or Olema Pharmaceuticals?
Olema Pharmaceuticals (OLMA) is larger, with a market capitalization of $694.73M compared with $662.35M for Nuvectis Pharma (NVCT).
Which stock has performed better over the past year, NVCT or OLMA?
NVCT returned +232.08% over the past 12 months, compared with -23.95% for OLMA (price return, excluding dividends). Past performance does not predict future results.
Are Nuvectis Pharma and Olema Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.